We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?
Read MoreHide Full Article
On Jan 3, we issued an updated report on VIVUS, Inc. . VIVUS’ three-month share price movement shows that the stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry. Specifically, the company gained 3.6% during this period, while the industry lost 8.2%.
The company's portfolio comprises two drugs – Qsymia for chronic weight management and Stendra (EU trade name: Spedra) for erectile dysfunction (ED).
Qsymia, VIVUS’ key drug, is the first weight loss product to be approved by the FDA in 13 years. However, sales of the drug have been lackluster so far. Its uptake has been slow due to high out-of-pocket costs for patients owing to the lack of reimbursement for the product. Healthcare providers are often hesitant to treat obesity proactively despite the presence of evidence related to cardiometabolic benefits of weight loss among overweight and obese individuals.
Qsymia faces intense competition too. The branded obesity market has quite a few established players including Arena Pharmaceuticals, Inc.’s Belviq, Novo Nordisk’s Saxenda and Orexigen Therapeutics, Inc.’s Contrave.
VIVUS is working on ramping up Qsymia sales through the expansion of reimbursement payments and promotional initiatives. The company is also striving to improve patient access while reducing out-of-pocket costs for Qsymia. Moreover, the company is pursuing several programs to increase the utilization of the drug for the eligible patient population. In Jun 2016, the company upgraded a Qsymia Patient Savings Offer in order to attract new patients and offer long-term support related to weight management.
Another marketed product in the company’s portfolio is Stendra, approved for the treatment of ED. VIVUS has collaborations with several companies for the commercialization of Stendra. It has inked a licensing and commercialization deal with Sanofi (SNY - Free Report) for the approval and commercialization of the drug in Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia. Moreover, it has a deal with Italy-based privately held pharmaceutical company Menarini in over 40 European countries, Australia and New Zealand.
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?
On Jan 3, we issued an updated report on VIVUS, Inc. . VIVUS’ three-month share price movement shows that the stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry. Specifically, the company gained 3.6% during this period, while the industry lost 8.2%.
The company's portfolio comprises two drugs – Qsymia for chronic weight management and Stendra (EU trade name: Spedra) for erectile dysfunction (ED).
Qsymia, VIVUS’ key drug, is the first weight loss product to be approved by the FDA in 13 years. However, sales of the drug have been lackluster so far. Its uptake has been slow due to high out-of-pocket costs for patients owing to the lack of reimbursement for the product. Healthcare providers are often hesitant to treat obesity proactively despite the presence of evidence related to cardiometabolic benefits of weight loss among overweight and obese individuals.
Qsymia faces intense competition too. The branded obesity market has quite a few established players including Arena Pharmaceuticals, Inc.’s Belviq, Novo Nordisk’s Saxenda and Orexigen Therapeutics, Inc.’s Contrave.
VIVUS is working on ramping up Qsymia sales through the expansion of reimbursement payments and promotional initiatives. The company is also striving to improve patient access while reducing out-of-pocket costs for Qsymia. Moreover, the company is pursuing several programs to increase the utilization of the drug for the eligible patient population. In Jun 2016, the company upgraded a Qsymia Patient Savings Offer in order to attract new patients and offer long-term support related to weight management.
Another marketed product in the company’s portfolio is Stendra, approved for the treatment of ED. VIVUS has collaborations with several companies for the commercialization of Stendra. It has inked a licensing and commercialization deal with Sanofi (SNY - Free Report) for the approval and commercialization of the drug in Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia. Moreover, it has a deal with Italy-based privately held pharmaceutical company Menarini in over 40 European countries, Australia and New Zealand.
VIVUS INC Price and Consensus
VIVUS INC Price and Consensus | VIVUS INC Quote
Zacks Rank
VIVUS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>